CJMB — CALLAN JMB INC.

Nasdaq · Industrials · Professional Services · CIK 2032545 ·
Last close
$0.80
Market Cap
$4.50M
52W High
$2.08
52W Low
$0.65
ADV30
347,472
Next earnings
Callan JMB Inc., through its subsidiary, Coldchain Technology Services, LLC provides thermal management logistics solutions to the life sciences industry in United States. It offers logistics solutions and services utilized for frozen shipping in the life sciences industry, including personalized medicine, cell therapies, stem cells, cell lines, vaccines, diagnostic materials, semen, eggs, embryos, cord blood, organs, biopharmaceuticals, infectious substances, and other commodities. The company also provides emergency preparedness services, which includes managing their building sites, medical stockpiles of equipment, and supplies and responding to state or local emergencies; specialty temperature-regulating packaging; technical services; and advanced monitoring sentry technology. The company was founded in 2006 and is headquartered in Spring Branch, Texas.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 1,106,143 427,235 -1,701,188 -3,215,054 5,710,395 1,415,566 4,110,862
Dec 2025 1,160,574 354,271 -1,968,418 -2,593,039 5,775,701 2,130,758 3,447,662
Sep 2025 1,446,917 493,307 -1,879,158 -2,731,341 7,736,180 2,789,744 3,560,528
Jun 2025 1,666,309 643,870 -1,402,667 -1,397,523 8,965,681 4,224,151 3,140,394

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-4,546,724
Investing CF
$-616,896
Financing CF
$5,196,433
CapEx
$-617,189
Dividends Paid
$0
Buybacks
EPS Diluted TTM
$-1.43
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-10,260,014
Inventory
$243,285
Receivables
$343,246
ST Investments
EBIT TTM
$-7,962,782
Pretax Income TTM
$-7,965,457
Interest Exp TTM
$2,675
Analysts

Yahoo Snapshot (yfinance, live)

Total Revenue
$5,723,178
EBITDA
$-6,340,539
Free Cash Flow
$-2,577,123
Enterprise Value
$5,540,047
Total Cash
$2,130,758
Total Debt
$1,987,164
Shares Out
5,646,118
Trailing EPS
$-2.09
Book Value
$0.48
ROE
-289.6%
ROA
-74.7%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 5,723,178 -6,492,491 -7,966,366 5,775,701 3,447,662 -4,546,724
Dec 2024 6,563,412 -2,274,814 -2,293,648 5,082,549 1,909,191 540,353
Dec 2023 13,202,459 2,202,063 2,181,108 9,705,529 910,269 6,995,646
Dec 2022 22,767,198 6,297,634 6,221,016 15,250,558 1,239,510 9,363,616

Peers — same industry

TickerNameMarket CapLastDaily %
BAOS Baosheng Media Group Holdings Ltd $4.54M $2.96
CLIK Click Holdings Ltd. $4.55M $1.55
NOTE FiscalNote Holdings, Inc. $4.68M $0.18
WAI Top KingWin Ltd $4.24M $1.85
BIYA Baiya International Group Inc. $4.16M $1.65

News headlines (Yahoo Finance, 1h cache)

Insiders Give Up US$84k As Callan JMB Stock Drops To US$0.79
2026-05-24 12:31 · Yahoo
Callan JMB Expands Long-Standing Public Sector Infrastructure Engagement
2026-05-20 13:00 · Yahoo
Callan JMB Launches The Atlas Complex in Alabama to Successfully Achieve the Capture of Significant Pharmaceutical Onshoring Demand and Expand U.S. Supply Chain Infrastructure
2026-04-20 12:00 · Yahoo
Callan JMB Issues Statement on Recently Filed Lawsuit by Eddie Patent Holdings LLC
2026-04-17 21:00 · Yahoo
Callan JMB Successfully Deploys Rapid Redistribution of Critical Pharmaceuticals to Combat Localized Disease Outbreaks for Longstanding Customer
2026-04-07 12:45 · Yahoo
Callan JMB Reports Full Year 2025 Financial Results and Provides Business Update
2026-03-31 20:05 · Yahoo
Callan JMB Supports U.S. Scale-Up of Multi-Indication Immune Platform with Phase 2b/3 Advancement
2026-03-27 12:45 · Yahoo
DifGen Pharmaceuticals and Aveva Drug Delivery Systems Lead U.S. Technology Transfer and Platform Development Collaboration for Multi-Indication Immune Restoration Therapy with Active IND Programs and
2026-03-25 12:37 · Yahoo
Callan JMB Inc. to Oversee Manufacturing and Quality Control of Attune Biotech’s IND Clinical Trials for lodonal™ in the Treatment of Long COVID
2026-03-11 12:45 · Yahoo
Updated Lineup Announced for the iAccess Alpha Virtual Best Ideas Spring Investment Conference March 10-11, 2026
2026-03-10 13:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.